Skip to content

    Tata Elxsi Q1 FY26 earnings call

    TATAELXSI
    Information Technology·10 Jul 2025
    Management Summary

    Tata Elxsi reported Q1 FY26 operating revenue of INR 892.1 crores, with EBITDA margin at 20.9% and PBT margin at 21.1%. The quarter was challenging due to geopolitical uncertainty and industry-specific issues, leading to QoQ declines in Media & Communication (-5.5%) and Healthcare & Life Sciences (-6.7%). The transportation business remained flat in constant currency. Management expects recovery in these segments and gradual margin improvement over the coming quarters, aiming for 29-30% EBITDA in the medium term.

    Highlights

    6
    • Operating revenue of INR892.1 crores.

    • Transportation business, representing over 50% of revenues, exited flat in constant currency terms.

    • Secured two strategic deal wins in the off-highway segment for AD-ADAS and connected vehicles.

    • Announced a strategic multimillion dollar design digital deal with a U.S. tech giant for next-generation AI and product feature development.

    • Reported two key wins in Healthcare, including a pharma and biotech leader from Europe and a Medtech leader from Japan.

    • Anticipates continued recovery and growth in transportation, backed by deals won, a healthy pipeline, and a new customer logo.

    Concerns

    5
    • EBITDA margin stood at 20.9% and PBT margin at 21.1%, indicating compression from prior levels.

    • The quarter was challenging due to geopolitical uncertainty and industry/customer-specific issues impacting R&D spend and deal closures.

    • Media and Communication business reported a decline of 5.5% QoQ in constant currency.

    • Healthcare & Life Sciences segment declined 6.7% QoQ in constant currency, affected by tariff-related impact on medical devices.

    • Automotive industry remains in a state of flux with China business and Tier 1 supplier challenges.

    What Changed2

    vs Q2 FY26

    Guidance items9 → 10 (+1)Risks discussed4 → 6 (+2)

    Key financials

    Single quarter

    03 metrics
    1. 01Operating Revenue₹892.1 Cr
    2. 02EBITDA Margin20.9%
    3. 03PBT Margin21.1%

    Segment breakdown

    Transportation
    50% Revenue Contribution0% Constant Currency Growth
    Media & Communication
    -5.5% Constant Currency Growth
    Healthcare & Life Sciences
    -6.7% Constant Currency Growth
    List

    Order Book

    medium confidence

    Pipeline

    deal pipeline tcv

    Healthy pipeline of large deals and new customer logos across various segments and geographies.

    Cancellations / Deferrals

    • deferred:New projects for two large US Healthcare customers were put on pause due to lack of clarity and uncertainties.

    "Management highlighted several strategic deal wins and a healthy pipeline, with ramp-ups of previous deals accelerating. However, specific TCV numbers for the quarter were not disclosed, and some projects were paused due to market uncertainties."

    Source:
    Prepared remarks

    Guidance & targets

    10
    CategoryTargetPriority
    Revenue
    Media & Communication Growth
    Growth
    High
    Revenue
    Healthcare & Life Sciences Recovery
    Recovery
    High
    Revenue
    Largest Customer (JLR) Outlook
    Stay steady
    High
    Revenue
    Transportation Business Growth
    Continued recovery and growth
    High
    Revenue
    Defense & Aerospace Revenue
    INR 50 crores
    Medium
    Revenue
    Media & Communication Large Deal Ramp-up
    Full ramp-up
    High
    Margin
    Overall Margin Improvement
    Gradual pull back
    High
    Margin
    EBITDA Margin Profile
    29-30%
    High
    Compensation
    Wage Hikes
    Will happen
    High
    Tax Rate
    Normalized Tax Rate
    North of 25%
    High

    What to watch in Q2 FY26

    5

    Media & Communication segment growth

    Q2 FY26
    CurrentDeclined 5.5% QoQ in Q1 FY26
    TargetReturn to growth

    Why it matters

    This segment is expected to recover in the next quarter, impacting overall revenue growth.

    We expect to bring back growth in this vertical in Q2 on the back of the deal ramp-ups and healthy deal pipeline.

    Risks & concerns

    6
    RiskSeverity

    Geopolitical uncertainty and industry/customer-specific issues impacting R&D spend and deal closures

    The quarter was challenging across key regions with geopolitical uncertainty and industry and customer-specific issues impacting R&D spend and deal closures across geographies.Management acknowledged

    high

    Automotive industry state of flux, China business/tariff uncertainties, and challenged Tier 1 supplier business

    Automotive industry is still in the state of flux with the China business and tariff-related uncertainties, casting a cloud on R&D strategy and spend, while the Tier 1 supplier business continues to be challenged.Management acknowledged

    high

    Subdued business environment and structural issues in Media & Communication industry

    While the overall business environment in this industry continues to be subdued, we have been working on shaping some large deals... the market currently, I think, is in a very, very difficult situation.Management acknowledged

    medium

    Healthcare & Life Sciences segment decline due to tariff-related impact on medical devices and US customer uncertainty

    Healthcare & Life Sciences segment declined 6.7% quarter-on-quarter in constant currency primarily affected by tariff-related impact on medical devices with two key customers in the U.S.Management acknowledged

    medium

    Margin pressure from large consolidation deals and rate resets

    The large consolidation deals... puts a little bit of pressure on our margins... our entire portfolio of business in that particular customer, the rates have been reset to a lower per unit rate because of the commercial construct of that deal.Management acknowledged

    high

    AI/GenAI not a quick fix for productivity due to legal issues and complexity

    the impact of AI is not going to be very dramatic as we speak, right? There are a lot of legal issues, customers are talking of open-ended liabilities... GenAI is a panacea for all issues that we're going to have.Management acknowledged

    low

    Q&A highlights

    8

    “in the last quarter, we did see good ramp ups of the deals that we had closed in the previous quarters, and we expect that trend to continue in the upcoming quarters as well. So, our US market is still a little bit slow. But other markets, we see a much better visibility, deal closures as well as ramp ups happening.”

    Clarifies regional performance and the accelerating ramp-up of previously won deals in the automotive sector.

    asked by Bhavik Mehta

    3 min read8 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance Overview and Challenges

    Tata Elxsi reported an operating revenue of INR 892.1 crores for Q1 FY26, with an EBITDA margin of 20.9% and PBT margin of 21.1%. The quarter was marked by challenges including geopolitical uncertainty🌐 and industry/customer-specific issues, which impacted R&D spend and deal closures across geographies. This environment contributed to a subdued performance in certain segments.

    02

    Transportation Business Resilience and Growth Outlook

    The transportation business, which accounts for over 50% of total revenues, demonstrated resilience by remaining flat in constant currency terms. The company secured two strategic deal wins in the off-highway segment for AD-ADAS and connected vehicles. Management noted that ramp-ups of large deals from previous quarters are accelerating, and they anticipate continued recovery and growth for the transportation business throughout the rest of the year, supported by a healthy pipeline and new customer logos.

    03

    Media & Communication Segment: Decline and Expected Q2 Recovery

    The Media and Communication business experienced a 5.5% QoQ decline in constant currency. This dip was largely attributed to transition investments associated with large consolidation deals announced in Q4 FY25. Despite the overall subdued industry environment, management expects this vertical to return to growth in Q2 FY26, driven by ongoing deal ramp-ups and a robust deal pipeline. Full ramp-up of a significant deal in this segment is projected by H2 FY26.

    04

    Healthcare & Life Sciences Segment: Q1 Setback and H2 Recovery Plan

    The Healthcare & Life Sciences segment saw a 6.7% QoQ decline in constant currency. This was primarily due to tariff-related impacts on medical devices, affecting two key U.S. customers who had paused new projects. These projects are expected to commence in Q2 FY26, and the company anticipates a recovery in this service line in H2 FY26. New client wins, including a pharma/biotech leader from Europe and a Medtech leader from Japan, are expected to contribute to future growth.

    05

    Margin Trajectory and Medium-Term Targets

    Current margins were pressured by revenue degrowth and the lower commercial terms associated with new large consolidation deals. Management expressed confidence in gradually pulling back margins over the next three quarters through operational efficiencies. The company's medium-term focus is to return to its historical EBITDA margin profile of 29-30%. Wage hikes for junior employees are planned from Q3 FY26, specifically in the October timeframe.

    06

    Strategic Shift Towards OEMs and New Vertical Development

    Tata Elxsi's revenue from OEMs now constitutes 72-75% of its total, reflecting a strategic alignment with the industry trend of passenger car makers taking on more roles previously handled by Tier 1 suppliers. The company continues to invest in new adjacencies, particularly aerospace and defense, having ramped up a 150-person team and built capabilities in drones and eVTOLs. A revenue target of INR 50 crores is set for this new vertical in FY26, with significant ramp-up expected in the next 2-3 years.

    07

    AI/GenAI Adoption and Realistic Expectations

    While Tata Elxsi is actively leveraging AI and GenAI and engaging with customers on these technologies, management provided a cautious outlook on their immediate impact. They noted that unlike IT or BPO sectors, AI's impact on headcount and productivity in engineering is not yet dramatic, citing legal issues, open-ended liabilities, and the complex nature of projects. Management emphasized that AI/GenAI is not a 'panacea' for all business challenges.

    08

    Tax Rate Adjustment Due to SEZ Benefits

    The company's tax rate for Q1 FY26 increased to approximately 27%. This rise is attributed to the phasing📎 out of SEZ benefits, with the tax bracket moving from 100% to 50%. Management expects the normalized tax rate to stabilize north of 25% going forward, impacting net profitability.

    This is an AI-generated summary of a publicly available earnings call transcript.